Praxis Precision Medicines, Inc. Announces Pricing of $525 Million Public Offering

Praxis Precision Medicines, Inc. has announced the pricing of a $525 million public offering of its stock135.

The offering is scheduled to close on or about October 20, 2025, subject to customary closing conditions and market conditions35.

Lead book-runners for the offering include TD Cowen, Piper Sandler, and Guggenheim3.

News of the offering led to an 8% rise in Praxis Precision Medicines' shares in pre-market trading6.

Praxis Precision Medicines is a clinical-stage biopharma focused on therapies for central nervous system disorders2.

The capital raised is expected to support ongoing research, development, and corporate operations, though specific use of proceeds was not detailed in the announcement135.

Sources:

1. https://markets.financialcontent.com/wral/article/gnwcq-2025-10-17-praxis-precision-medicines-inc-announces-pricing-of-525-million-public-offering

2. https://www.globenewswire.com/news-release/2023/06/16/2689497/0/en/Praxis-Precision-Medicines-Inc-Announces-Pricing-of-59-1-Million-Public-Offering.html

3. https://www.streetinsider.com/Equity+Offerings/Praxis+Precision+Medicines+prices+$525+million+stock+offering/25467708.html

5. https://www.biospace.com/press-releases/praxis-precision-medicines-inc-announces-pricing-of-525-million-public-offering

6. https://www.ainvest.com/news/praxis-precision-medicines-raises-525m-public-share-offering-shares-rise-8-2510/